![\"Patient](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/02\/1770949887_255_.jpeg\"\/)
<\/p>\n
Image source: Getty Images.<\/p>\n
Why Johnson & Johnson might run into headwinds<\/p>\n
Despite strong recent performances, some will point to multiple challenges Johnson & Johnson is facing. First, several of its medicines have been targeted by government-led drug price negotiations. This will likely lead to lower sales for these therapies than the company would have generated otherwise. There is also the threat of patent cliffs. Last year, Johnson & Johnson lost patent exclusivity in the U.S. for Stelara, an immunology drug, forcing the company to compete with biosimilars.<\/p>\n
Even beyond patent cliffs, Johnson & Johnson faces stiff competition for some products whose sales are moving in the wrong direction as a result. One such example is Imbruvica, a cancer drug. Lastly, Johnson & Johnson is still dealing with thousands of lawsuits from plaintiffs who claim that its talc-based products gave them cancer. Can Johnson & Johnson perform well amid these challenges?<\/p>\n
![\"Johnson](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/02\/1770949887_479_.png\"\/)
<\/p>\n
Today’s Change<\/p>\n
(1.57%) $3.78<\/p>\n
Current Price<\/p>\n
$244.64<\/p>\n
Key Data Points<\/p>\n
Market Cap<\/p>\n
$580B<\/p>\n
Day’s Range<\/p>\n
$239.70 – $246.35<\/p>\n
52wk Range<\/p>\n
$141.50 – $246.35<\/p>\n
Volume<\/p>\n
522K<\/p>\n
Avg Vol<\/p>\n
9.1M<\/p>\n
Gross Margin<\/p>\n
75.27%<\/p>\n
Dividend Yield<\/p>\n
2.13%<\/p>\n
A resilient business<\/p>\n
One of Johnson & Johnson’s best assets is its vast portfolio of medicines across many therapeutic areas. That ensures that, even with competition — from biosimilars or otherwise — its sales and earnings generally move in the right direction. That’s what happened last year, even with declining revenue from Stelara, Imbruvica, and others, Johnson & Johnson posted strong results. And the company’s guidance for the fiscal year 2026 implies it will perform well, too<\/a>.<\/p>\n Johnson & Johnson’s diversification, including within its medical device<\/a> division, where it is close to launching a robotic-assisted surgery device that will create more growth opportunities, is also a powerful hedge against drug price negotiations. Further, the company has a rock-solid balance sheet, with the highest credit rating available, evidence that it can survive its legal troubles.<\/p>\n